Longeveron Inc Stock Price, News & Analysis

Longeveron Inc. (LGVN) announced a new Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs (VA) to add a Miami VA clinical site to its Phase 2 Alzheimer’s Disease trial. This collaboration marks the third CRADA with the VA, which also includes studies on aging frailty and Covid-19. The Phase 2 trial, named CLEAR MIND, will explore the safety and efficacy of Lomecel-B in treating mild Alzheimer’s, enrolling 48 patients. Recent peer-reviewed data indicated that Lomecel-B shows promise in slowing cognitive decline and improving quality of life.

Longeveron Inc. (NASDAQ: LGVN) has appointed Dr. K. Chris Min as Chief Medical Officer, effective April 4, 2022. Dr. Min will oversee global clinical development and regulatory strategy, particularly focusing on advancing Lomecel-B through pivotal trials. He brings over a decade of industry experience, including roles at Enterin and Cerevel Therapeutics. The company aims to progress Lomecel-B's development for conditions like Alzheimer's and Hypoplastic Left Heart Syndrome, with clinical trials expanding to Asia.

Longeveron Inc. (NASDAQ: LGVN) announced positive results from a Phase 1 trial of Lomecel-B for Alzheimer's disease, published in Alzheimer’s & Dementia. The study met its primary safety endpoint, showing that Lomecel-B was well tolerated, with no serious side effects observed. Preliminary findings suggest Lomecel-B may slow cognitive decline and improve patient quality of life. A Phase 2 trial has commenced, exploring single vs. multiple doses. The study indicates a potential for Lomecel-B to address multiple Alzheimer’s pathology features, as highlighted by encouraging changes in cognitive and brain health assessments.

Longeveron, a clinical-stage biotechnology company, presented at the Second Euro-Geroscience Conference on March 24-25, 2022, focusing on cellular therapies for aging-related conditions. Notable presentations included "Targeting Frailty with Stem Cells" and results for LOMECEL-B as a geroscience therapeutic candidate. Longeveron's lead product, derived from medicinal signaling cells, aims to treat conditions such as Aging Frailty and Alzheimer's. The company is advancing toward pivotal Phase 3 trials with regulatory approval in view.

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company, announced that CEO Geoff Green will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022. The virtual presentation is scheduled from 2:00 to 2:30 p.m. ET and will be accessible via Longeveron's website. The company specializes in cellular therapies targeting chronic, aging-related, and life-threatening conditions, focusing on its lead product, LOMECEL-B™. Longeveron is currently conducting Phase 1 and 2 trials for various conditions, including Alzheimer’s disease and Aging Frailty.

Longeveron (NASDAQ: LGVN) reported significant advancements in clinical trials for Lomecel-B, focusing on Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and COVID-related Acute Respiratory Distress Syndrome. The company received FDA designations for HLHS and raised $20.5 million in a private placement to support ongoing research. Despite a decline in revenue from $1.3 million in 2021 to $5.6 million in 2020, Longeveron expects sufficient cash to fund operations into 2024. Multiple data publications and a conference call to discuss results are scheduled for March 11, 2022.

Longeveron Inc. (NASDAQ: LGVN) plans to release its fourth quarter and year-end 2021 financial results on March 11, 2022, before U.S. markets open. A conference call will follow at 8:30 a.m. EST where management will discuss the results and provide a corporate update. The company focuses on cellular therapies for aging-related and life-threatening conditions, with its lead product LOMECEL-B undergoing Phase 1 and 2 trials for indications like Alzheimer’s disease and Aging Frailty.

Longeveron, a clinical stage biotechnology company focused on cellular therapies for chronic and aging-related conditions, announced that CEO Geoff Green will present at the Q1 Virtual Investor Summit on March 8, 2022, from 2:00 to 2:30 p.m. ET. The presentation will be available via a live webcast on the company's website, with an archived replay to follow. Longeveron's lead product, Lomecel-B, is derived from young adult bone marrow and aims to treat disorders linked to aging. The company seeks to advance its therapies toward regulatory approvals and commercialization.

Longeveron Inc. (NASDAQ: LGVN) appointed Todd Girolamo to its Board of Directors, bringing extensive legal, finance, and M&A experience. Girolamo is currently serving as Chief Legal Officer and Senior VP at Caladrius Biosciences. His expertise in biopharma, especially in cell and gene therapy, is expected to enhance Longeveron's clinical development efforts for its lead product, Lomecel-B, which is being tested for conditions like aging frailty and Alzheimer's. The company aims to advance its therapies towards potential regulatory approvals and commercialization.